Skip to main content
. 2013 Dec 31;45(4):251–262. doi: 10.4143/crt.2013.45.4.251

Table 1.

Completed clinical studies of single-agent arginine depletors in advanced cancer

graphic file with name crt-45-251-i001.jpg

HCC, hepatocellular carcinoma; CR, complete response; PR, partial response; SD, stable disease; PFS, progression-free survival; NO, nitric oxide; MOA, mechanism of action; ASS1, argininosuccinate synthetase 1; n/a, not available; PMR, partial metabolic response; OBD, optimal biological dose; BSC, best supportive care; RECIST, Response Evaluation Criteria in Solid Tumors; IHC, immunohistochemistry. a)From diagnosis.